The latest biotech startup from Seattle-based Accelerator, Xori, has received $2.1 million out of a $4.5 million financing round, according to a regulatory filing. The company (pronounced Chore-ee) is testing technology from the lab of Nancy Maizels at the University of Washington, which seeks to develop antibody drugs through a new technique in genetically modified chicken cells, as I described in this feature story yesterday.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
